| 000 | 01556 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516015635.0 | ||
| 264 | 0 | _c20110228 | |
| 008 | 201102s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1038/clpt.2010.268 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMaeda, A | |
| 245 | 0 | 0 |
_aDifferential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cFeb 2011 |
||
| 300 |
_a229-33 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xgenetics |
| 650 | 0 | 4 | _aClopidogrel |
| 650 | 0 | 4 |
_aCoronary Artery Disease _xdrug therapy |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C19 |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPlatelet Aggregation _xdrug effects |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 |
_aTiclopidine _xanalogs & derivatives |
| 700 | 1 | _aAndo, H | |
| 700 | 1 | _aAsai, T | |
| 700 | 1 | _aIshiguro, H | |
| 700 | 1 | _aUmemoto, N | |
| 700 | 1 | _aOhta, M | |
| 700 | 1 | _aMorishima, M | |
| 700 | 1 | _aSumida, A | |
| 700 | 1 | _aKobayashi, T | |
| 700 | 1 | _aHosohata, K | |
| 700 | 1 | _aUshijima, K | |
| 700 | 1 | _aFujimura, A | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 89 _gno. 2 _gp. 229-33 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/clpt.2010.268 _zAvailable from publisher's website |
| 999 |
_c20466845 _d20466845 |
||